• Pioglitazone: Selective PPARγ Agonist for Metabolic & Inf...

  2026-04-01

  Pioglitazone, a potent and selective PPARγ agonist, offers unique experimental versatility for dissecting metabolic, inflammatory, and neurodegenerative pathways. This guide delivers actionable protocols, troubleshooting strategies, and cutting-edge applications—backed by recent STAT-1/STAT-6 pathway research and APExBIO's quality assurance—to empower robust, reproducible bench research.

• GLP-1 (9-36) amide: Reliable Antagonist for GLP-1R Signal...

  2026-04-01

  This article provides scenario-driven guidance for biomedical researchers tackling challenges in GLP-1 receptor signaling and metabolic regulation, focusing on the practical use of GLP-1 (9-36) amide (SKU B5404). Drawing on validated protocols, peer-reviewed data, and product-specific attributes, it demonstrates how this peptide antagonist supports reproducibility, sensitivity, and experimental clarity in endocrinology and diabetes research.

• HOBt (1-Hydroxybenzotriazole): Precision in Peptide Coupl...

  2026-03-31

  Explore how HOBt (1-Hydroxybenzotriazole) acts as a racemization inhibitor for peptide synthesis, enabling advanced amide bond formation and expanding the frontiers of peptide chemistry. This article provides in-depth mechanistic insights, comparative analysis, and novel applications, surpassing traditional perspectives.

• BIIE 0246: Selective Neuropeptide Y Y2 Receptor Antagonis...

  2026-03-31

  BIIE 0246 is a nanomolar-potency, selective neuropeptide Y Y2 receptor antagonist optimized for neuroscience and metabolic research. Its well-validated pharmacology enables precise interrogation of presynaptic inhibition, feeding behavior, and anxiety models in both in vitro and in vivo systems.

• Gastrin I (human): Molecular Insights and Emerging Roles ...

  2026-03-30

  Explore the multifaceted role of Gastrin I (human) as a gastric acid secretion regulator and selective CCK2 receptor agonist. This article uncovers molecular mechanisms, advanced organoid applications, and new research perspectives that go beyond standard assay protocols.

• 2-Deoxy-D-glucose: Advanced Insights into Glycolysis Inhi...

  2026-03-30

  Explore the multifaceted roles of 2-Deoxy-D-glucose as a glycolysis inhibitor in cancer metabolism, viral infection research, and immune modulation. This in-depth article provides new mechanistic insights and highlights novel applications, setting it apart from standard guides.

• 2'3'-cGAMP (Sodium Salt): Decoding STING-Mediated Radiore...

  2026-03-29

  Explore how 2'3'-cGAMP (sodium salt) uncovers new mechanisms in the cGAS-STING signaling pathway, connecting cyclic dinucleotide signaling to radiotherapy resistance and cancer immunotherapy. Discover unique insights into metabolic adaptation and STING pathway modulation, grounded in the latest research.

• 2-Deoxy-D-glucose: Advanced Mechanistic Insights for Canc...

  2026-03-28

  Explore the advanced mechanisms of 2-Deoxy-D-glucose as a glycolysis inhibitor in cancer metabolism research and viral replication inhibition. This article offers unique, in-depth analysis of metabolic pathway modulation and experimental best practices using APExBIO's reagent.

• 2-Deoxy-D-glucose: Precision Glycolysis Inhibition for Ca...

  2026-03-27

  2-Deoxy-D-glucose (2-DG) is a validated glycolysis inhibitor used to study cancer metabolism and viral replication, showing potent cytotoxicity in KIT-positive GIST cell lines and synergy with chemotherapeutics. As a metabolic oxidative stress inducer, it offers precise, reproducible control of ATP synthesis inhibition. APExBIO's 2-DG (SKU B1027) is optimized for robust, translational workflows.

• 2-Deoxy-D-glucose (2-DG, B1027): Reliable Glycolysis Inhi...

  2026-03-27

  This article delivers scenario-driven, evidence-based guidance for deploying 2-Deoxy-D-glucose (SKU B1027) in cell viability, proliferation, and metabolic stress assays. Drawing on validated protocols and recent literature, it addresses common pitfalls with quantitative context and demonstrates why APExBIO’s formulation offers reproducibility and workflow confidence for biomedical researchers.

• Gastrin I (human): Advanced Insights into CCK2 Receptor S...

  2026-03-26

  Explore how Gastrin I (human) serves as a pivotal CCK2 receptor agonist for in vitro gastric acid secretion pathway research. This article uniquely bridges foundational peptide pharmacology with cutting-edge organoid and stem cell models, providing unmatched depth for gastrointestinal physiology studies.

• GLP-1 (9-36) Amide: Advancing Precision in GLP-1 Receptor...

  2026-03-26

  Explore the advanced mechanistic insights and experimental applications of GLP-1 (9-36) amide, a leading GLP-1 receptor antagonist peptide. This article uniquely examines receptor cross-reactivity, assay design, and translational relevance in type 2 diabetes research.

• Parathyroid hormone (1-34) (human): Atomic Mechanisms, Be...

  2026-03-25

  Parathyroid hormone (1-34) (human) is a potent parathyroid hormone 1 receptor agonist used in bone metabolism research and advanced kidney assembloid models. This article delivers atomic, verifiable facts and structured insights into its molecular action, experimental benchmarks, and workflow integration for calcium homeostasis and disease modeling.

• BIIE 0246: Selective Y2 Receptor Antagonist for Neuroscie...

  2026-03-25

  BIIE 0246, supplied by APExBIO, empowers researchers with nanomolar-selective inhibition of the neuropeptide Y Y2 receptor, unlocking detailed mechanistic studies in feeding behavior, anxiety, and cardiac arrhythmia. Its reproducible effects and protocol versatility set a new benchmark for dissecting neuropeptide Y signaling in central and peripheral models.

• BIIE 0246 and the Adipose-Neural Axis: Strategic Guidance...

  2026-03-24

  This thought-leadership article, authored by the head of scientific marketing at a leading biotech company, provides a deep dive into the mechanistic roles of the neuropeptide Y Y2 receptor (Y2R), offering strategic guidance for translational researchers. It synthesizes the latest evidence on the adipose-neural axis—including the recent identification of neuropeptide Y signaling as a driver of cardiac arrhythmia—while positioning BIIE 0246 as the essential tool for dissecting these complex pathways. Beyond typical product communications, this piece explores experimental, competitive, and visionary perspectives, charting the next horizon for feeding behavior, anxiety, metabolic, and cardiovascular research.

16110 records 1/1074 page Next 12345 下5页 Last page